Premier Path Wealth Partners LLC Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Premier Path Wealth Partners LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 34.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,074 shares of the company's stock after acquiring an additional 4,111 shares during the period. Premier Path Wealth Partners LLC's holdings in Johnson & Johnson were worth $2,325,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. IFS Advisors LLC boosted its holdings in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares during the period. Highline Wealth Partners LLC acquired a new stake in Johnson & Johnson in the third quarter worth approximately $31,000. RPg Family Wealth Advisory LLC acquired a new position in Johnson & Johnson during the third quarter worth about $35,000. Mowery & Schoenfeld Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after purchasing an additional 91 shares in the last quarter. Finally, Activest Wealth Management bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth $40,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.5 %

Shares of NYSE JNJ traded down $0.74 during midday trading on Monday, reaching $147.03. The stock had a trading volume of 10,678,393 shares, compared to its average volume of 6,880,262. The firm has a market cap of $353.99 billion, a price-to-earnings ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company's 50 day moving average price is $148.51 and its 200 day moving average price is $156.10. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.37%. Johnson & Johnson's dividend payout ratio (DPR) is currently 71.78%.

Insider Buying and Selling

In related news, Director Mark A. Weinberger purchased 1,000 shares of the business's stock in a transaction dated Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company's stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent analyst reports. Guggenheim increased their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a research note on Wednesday, November 6th. Bank of America reduced their target price on Johnson & Johnson from $166.00 to $160.00 and set a "neutral" rating for the company in a research report on Friday. StockNews.com downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an "equal weight" rating in a report on Wednesday, October 16th. Finally, Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a report on Wednesday, December 11th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $174.29.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.